2019
Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, Bosi E, Buckingham BA, Cefalu WT, Close KL, Cobelli C, Dassau E, DeVries JH, Donaghue KC, Dovc K, Doyle FJ, Garg S, Grunberger G, Heller S, Heinemann L, Hirsch IB, Hovorka R, Jia W, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Levine B, Mayorov A, Mathieu C, Murphy HR, Nimri R, Nørgaard K, Parkin CG, Renard E, Rodbard D, Saboo B, Schatz D, Stoner K, Urakami T, Weinzimer SA, Phillip M. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care 2019, 42: 1593-1603. PMID: 31177185, PMCID: PMC6973648, DOI: 10.2337/dci19-0028.Peer-Reviewed Original Research
2013
Reduced Hypoglycemia and Increased Time in Target Using Closed-Loop Insulin Delivery During Nights With or Without Antecedent Afternoon Exercise in Type 1 Diabetes
Sherr JL, Cengiz E, Palerm CC, Clark B, Kurtz N, Roy A, Carria L, Cantwell M, Tamborlane WV, Weinzimer SA. Reduced Hypoglycemia and Increased Time in Target Using Closed-Loop Insulin Delivery During Nights With or Without Antecedent Afternoon Exercise in Type 1 Diabetes. Diabetes Care 2013, 36: 2909-2914. PMID: 23757427, PMCID: PMC3781513, DOI: 10.2337/dc13-0010.Peer-Reviewed Original ResearchConceptsNocturnal hypoglycemiaType 1 diabetesAfternoon exerciseInsulin deliveryAntecedent exerciseTarget blood glucose rangeCL insulin deliveryClosed-loop insulin deliveryLoop insulin deliveryTarget rangeBlood glucose levelsBlood glucose rangeMaximum heart rateCL controlBrisk treadmillReduced hypoglycemiaSedentary dayExercise dayPercentage of timeGlucose levelsHeart rateGlucose valuesType 1Random orderStudy periodThe Effects of Inpatient Hybrid Closed-Loop Therapy Initiated Within 1 Week of Type 1 Diabetes DiagnosisDiabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups*
Buckingham B, Beck R, Ruedy K, Cheng P, Kollman C, Weinzimer S, DiMeglio L, Bremer A, Slover R, Cantwell M. The Effects of Inpatient Hybrid Closed-Loop Therapy Initiated Within 1 Week of Type 1 Diabetes DiagnosisDiabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups*. Diabetes Technology & Therapeutics 2013, 15: 401-408. PMID: 23570538, PMCID: PMC3643224, DOI: 10.1089/dia.2013.0002.Peer-Reviewed Original ResearchConceptsType 1 diabetesMean glucose concentrationHybrid closed-loop controlMedian percentageHybrid closed-loop therapyType 1Sensor-augmented pump therapyPositive pancreatic autoantibodiesTrialNet Study GroupDays of diagnosisNormal glycemic controlΒ-cell functionGlucose concentrationClosed-loop therapyPancreatic autoantibodiesGlycemic controlSAP therapyPump therapyStudy groupGlucose levelsGlucose toxicityDay 2Day 3Glucose valuesTherapy
2009
Sustained Benefit of Continuous Glucose Monitoring on A1C, Glucose Profiles, and Hypoglycemia in Adults With Type 1 Diabetes
Bode B, Beck R, Xing D, Gilliam L, Hirsch I, Kollman C, Laffel L, Ruedy K, Tamborlane W, Weinzimer S, Wolpert H. Sustained Benefit of Continuous Glucose Monitoring on A1C, Glucose Profiles, and Hypoglycemia in Adults With Type 1 Diabetes. Diabetes Care 2009, 32: 2047-2049. PMID: 19675193, PMCID: PMC2768224, DOI: 10.2337/dc09-0846.Peer-Reviewed Original Research
2001
Endocrine aspects of the 22q11.2 deletion syndrome
Weinzimer S. Endocrine aspects of the 22q11.2 deletion syndrome. Genetics In Medicine 2001, 3: 19-22. PMID: 11339371, DOI: 10.1097/00125817-200101000-00005.Peer-Reviewed Original ResearchConceptsGrowth hormone deficiencyEndocrine disturbancesEndocrine disordersHormonal disordersAppropriate screeningHormone deficiencyEndocrine aspectsEndocrinological manifestationsPatientsDiGeorge syndromeDeletion syndromeSyndromeDisordersCurrent understandingHypoparathyroidismHyperthyroidismHypothyroidismDeletion
2000
Human Papillomavirus Type 16 E7 Oncoprotein Binds and Inactivates Growth-Inhibitory Insulin-Like Growth Factor Binding Protein 3
Mannhardt B, Weinzimer S, Wagner M, Fiedler M, Cohen P, Jansen-Dürr P, Zwerschke W. Human Papillomavirus Type 16 E7 Oncoprotein Binds and Inactivates Growth-Inhibitory Insulin-Like Growth Factor Binding Protein 3. Molecular And Cellular Biology 2000, 20: 6483-6495. PMID: 10938125, PMCID: PMC86123, DOI: 10.1128/mcb.20.17.6483-6495.2000.Peer-Reviewed Original ResearchMeSH KeywordsApoptosisBlotting, NorthernCell DivisionCell LineCells, CulturedDose-Response Relationship, DrugFluorescent Antibody TechniqueGlutathione TransferaseHumansInsulin-Like Growth Factor Binding Protein 3KeratinocytesOncogene Proteins, ViralPapillomavirus E7 ProteinsPrecipitin TestsProtein BindingRecombinant Fusion ProteinsTime FactorsTransfectionTumor Cells, CulturedTumor Suppressor Protein p53Two-Hybrid System Techniques